Skip to content

The Relationship Between Total Sialic Acid and Superoxide Dismutase and the Diagnosis and Prognosis of Lipoid Pneumonia

A Study to Explore the Correlation Between Total Sialic Acid Combined With Superoxide Dismutase and the Diagnosis and Prognosis of Lipoid Pneumonia

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06430008
Enrollment
160
Registered
2024-05-28
Start date
2024-05-01
Completion date
2024-12-31
Last updated
2024-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipid Pneumonia, Sialic Acid, Superoxide Dismutase

Brief summary

The goal of this observational study is to explore the correlation between total sialic acid combined with superoxide dismutase and the diagnosis and prognosis of lipid pneumonia in the patient with lipid pneumonia, cough, bacterial and fungal pneumonia, cryptogenic organizing pneumonia, pulmonary alveolar proteinosis, lung mucinous adenocarcinoma and pulmonary edema. The main question it aims to answer is: Whether superoxide dismutase (SOD) and total sialic acid (TSA) could be used as diagnostic markers to distinguish lipid pneumonia from patient with cough, and bacterial and fungal pneumonia, cryptogenic organizing pneumonia, pulmonary alveolar proteinosis, lung mucinous adenocarcinoma and pulmonary edema, whether SOD and TSA be associated with the prognosis of patients with lipid pneumonia? Participants will answer online survey questions about their symptoms, changes in oxygen status, and changes in the most recent CT image of the lung for up to 10 years after treatment. We will count participants' baseline data including: gender, age, smoking history, comorbidities, lung function, imaging findings, hormone use or not, ICU treatment, death or not, the type of cause of lipid pneumonia, how it is diagnosed, and their baseline SOD and TSA.

Interventions

None listed

Sponsors

Hu Yinan
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Age≥ 18 years old; 2. The diagnosis of lipoid pneumonia must be supported by lung biopsy pathological support or positive oil red O or Sudan staining in bronchoalveolar lavage fluid; 3. Patients with bacterial and fungal pneumonia must be supported by etiological evidence; 4. Patients with cryptogenic organizing pneumonia and pulmonary alveolar proteinosis must be supported by lung biopsy pathology; 5. Patients with lung mucinous adenocarcinoma must be supported by lung tissue biopsy; 6. Lung imaging of patients with pulmonary edema must show paving stone signs;

Exclusion criteria

1. Age< 18 years old; 2. The patient only has a history of lipid inhalation and no pathology or positive lipoid staining; 3. Co-infection with the corona virus disease 2019 at the onset of illness; 4. Pregnant

Design outcomes

Primary

MeasureTime frame
superoxide dismutaseAt the time of admission

Secondary

MeasureTime frame
sialic acidAt the time of admission
death or notWithin 10 years after discharge
neutrophil-to-lymphocyte ratioAt the time of admission

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026